Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
|Videos|March 14, 2014
Treatment Options for BCR After Local Therapy for Prostate Cancer
Author(s)Rana R. McKay, MD
Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, discusses treatment options for biochemical relapse after definitive local therapy for prostate cancer.
Advertisement
Clinical Pearls
Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, discusses treatment options for biochemical relapse after definitive local therapy for prostate cancer.
- Biochemical relapse is a heterogenous disease state and is likely related to tumor biology
- Classically, patients who have received a radical prostatectomy may be candidates for salvage radiation therapy with or without hormone therapies
- Patients who initially received primary radiation therapy may be candidates for salvage radical prostatectomy or hormone therapy
- In a previous study, patients in this space were essentially cured following treatment with docetaxel plus estramustine and ADT
- This trial, presented at the 2014 Genitourinary Cancers Symposium, aimed to determine the benefit of docetaxel plus bevacizumab and ADT
Advertisement
Related to this article
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
FDA expands nogapendekin alfa inbakicept plus BCG use to high-grade papillary-only BCG-unresponsive NMIBC, offering durable control and strong cystectomy-avoidance outcomes.
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies—yet gaps persist, and research funding uncertainty threatens future gains.
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
3
Retlirafusp Alfa Improves Overall Survival in Phase 3 Trial of HER2– Gastric Cancer
4
Dr Beck on the Practical Realities of Subcutaneous Oncology Drug Delivery
5